Enzolytics, Inc. (ENZC)
| Market Cap | 1.93M |
| Revenue (ttm) | 46.59K +26.0% |
| Net Income | -1.03M |
| EPS | -4.76 |
| Shares Out | 4.83B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 504,250 |
| Open | 0.0003 |
| Previous Close | 0.0004 |
| Day's Range | 0.0003 - 0.0004 |
| 52-Week Range | 0.0002 - 0.0013 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Enzolytics
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics, Inc. is ... [Read more]
Financial Performance
In 2011, Enzolytics's revenue was $52,807, an increase of 42.85% compared to the previous year's $36,968. Losses were -$882,928, -88.25% less than in 2010.
Financial StatementsNews
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of ...
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com ") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology, ...
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infec...
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
As well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Comp...
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
Updates on Results of Litigation ALLEN, TX / ACCESSWIRE / July 29, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collabora...
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ( enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam ...
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a wor...
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
ALLEN, TX / ACCESSWIRE / June 3, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") is thrilled to announce that the Company and Sagaliam Acquisition Corp ("SAGA") are negotiati...
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
ALLEN, TX / ACCESSWIRE / May 2, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the plan to form ETC Marketing Inc. ("ETC Marketing") in partnership with Third Coast Fulfillmen...
Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.
NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC P...
Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada
Offers Update on OTC Annual Report and Business Model ALLEN, TX / ACCESSWIRE / April 23, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com)(the "Company") today disclosed that on April 9, 2024, ...
Update on Formulation of New Business Strategy
INFORMATION ON ENZOLYTICS, INC. BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICER UPDATE ON FORMULATION OF NEW BUSINESS STRATEGY ALLEN, TX / ACCESSWIRE / April 12, 2024 / Enzolytics, Inc. (OTC PINK:ENZC)...
ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD
Board Appoints Officers ALLEN, Texas , March 25, 2024 /PRNewswire/ -- Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") On March 19t...
Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity
ALLEN, TX / ACCESSWIRE / January 16, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com). Enzolytics, Inc. has partnered with The Khalpey AI Lab to improve organ recovery, longevity, and ...
Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure
Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. Progress ALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https...
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
COLLEGE STATION, TX / ACCESSWIRE / September 18, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com). Enzolytics, Inc. announces today that it has executed the binding business combinatio...
Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")
Start date is expected by the end of 2023 / beginning of 2024. VIRO also offers an update on Diabetic trials and Sagaliam transaction.
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.
COLLEGE STATION, TX / ACCESSWIRE / September 5, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Compan...
Biogenysis' International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
COLLEGE STATION, TX / ACCESSWIRE / August 24, 2023 / Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation...
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
Reports on Business combination agreement progress ALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO") a wholly owned subsi...
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes
Progress on Sagaliam Acquisition Corp Transaction ALLEN, TX / ACCESSWIRE / August 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO"), a wholly owned subsi...
CORRECTION FROM SOURCE: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC
Expects to Issue Update on EMA Progress ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). CORRECTED Virogentics, Inc. ("VIRO") a wholly owned subsidi...
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials
ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"),...
Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.
COLLEGE STATION, TX / ACCESSWIRE / July 21, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" o...
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. ("ENZC" or the "Company") filed a Supplemental Information report today ...